Literature DB >> 10426811

Altered bcl-2 family expression during non-genotoxic hepatocarcinogenesis in mice.

J G Christensen1, E H Romach, L N Healy, A J Gonzales, S P Anderson, D E Malarkey, J C Corton, T R Fox, R C Cattley, T L Goldsworthy.   

Abstract

Dysregulation of apoptosis is an important component of multistage hepatocarcinogenesis. Members of the bcl-2 protein family are important in the regulation of apoptosis and their expression is altered in several cancers. The objectives of the present study were to determine whether the expression of members of the bcl-2 protein family are altered in mouse liver during acute treatment with non-genotoxic carcinogens and throughout non-genotoxic hepatocarcinogenesis. Acute treatment of B6C3F1 mice with phenobarbital resulted in increased levels of bcl-2 and decreased levels of bax protein, while acute treatment with WY-14,643 resulted in increased bcl-2 and BAG-1 protein in the liver. Following chronic treatment, altered hepatic foci and adenomas were classified as: small-cell, heterogeneous basophilic lesions (spontaneous or tetrachlorodibenzo-p-dioxin-induced); large-cell, homogeneous basophilic lesions (WY-14,643-induced); acidophilic lesions (phenobarbital- or chlordane-induced). Of the small-cell heterogeneous basophilic lesions, 86% of foci (31/36) and 85% of adenomas (35/41) exhibited increased bcl-2 protein levels compared with surrounding normal hepatocytes, whereas only 12.5% of foci (4/36) and 12% of adenomas (5/41) exhibited increased bcl-X(L) levels. Of the large-cell, homogenous, basophilic lesions, 100% of foci (3/3) and 90% of adenomas (9/10) expressed bcl-2 protein, whereas 100% of foci (3/3) and 80% of adenomas (8/10) exhibited increased bcl-X(L) protein levels compared with surrounding normal hepatocytes. Of the acidophilic lesions, the majority of foci (28/32, 88%) and adenomas (47/50, 94%) expressed increased bcl-X(L), whereas increased bcl-2 was observed in only 12.5% of acidophilic preneoplastic foci (4/32) and 14% of acidophilic adenomas (7/50). Of the carcinomas analyzed, 81% expressed increased bcl-2 (54/67), 78% expressed increased bcl-X(L) (52/67) and 69% expressed increased levels of both bcl-2 and bcl-X(L) (46/67). Collectively, only 8% of preneoplastic foci, 3% of adenomas and 1.5% of carcinomas did not express either bcl-2 or bcl-X(L). These results suggest that regulation of apoptotic proteins is altered during non-genotoxic carcinogenesis in mouse liver. Furthermore, there were both chemical- and lesion-specific aspects of expression of apoptotic proteins during hepatocarcinogenesis in mice.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10426811     DOI: 10.1093/carcin/20.8.1583

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  5 in total

1.  Dioxin exposure reduces the steroidogenic capacity of mouse antral follicles mainly at the level of HSD17B1 without altering atresia.

Authors:  Bethany N Karman; Mallikarjuna S Basavarajappa; Patrick Hannon; Jodi A Flaws
Journal:  Toxicol Appl Pharmacol       Date:  2012-08-06       Impact factor: 4.219

2.  Inductive effect of phytoglycoprotein (38 kDa) on G₀/G₁ arrest and apoptosis in diethylnitrosamine-treated ICR mice.

Authors:  Jin Lee; Kye-Taek Lim
Journal:  Mol Cell Biochem       Date:  2012-12-02       Impact factor: 3.396

3.  Stem cell factor and c-kit are involved in hepatic recovery after acetaminophen-induced liver injury in mice.

Authors:  Bin Hu; Lisa M Colletti
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2008-05-08       Impact factor: 4.052

4.  Effect of taurine on oxidative stress and apoptosis-related protein expression in trinitrobenzene sulphonic acid-induced colitis.

Authors:  M Giriş; B Depboylu; S Doğru-Abbasoğlu; Y Erbil; V Olgaç; H Aliş; G Aykaç-Toker; M Uysal
Journal:  Clin Exp Immunol       Date:  2008-01-28       Impact factor: 4.330

5.  Decreased expression of Bcl-x protein during hepatocarcinogenesis induced exogenously and endogenously in rats.

Authors:  Y Hatanaka; D Nakae; M Mutai; K Hashizume; Y Kamihara; N Kinoshita; Y Tani; G Danno Gi; S Ohta; Y Konishi; H Ashida
Journal:  Jpn J Cancer Res       Date:  2001-12
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.